Where Leaders in Oncology UniteAgainst Lung Cancer||To Share Knowledge||To Exchange||To Debate||To Advance Care||To Fight Cancer||To Drive Progress||To Provide Insights
CME-certified
Expert-Driven Education & Insights
LATEST
Sessions On Demand
RESHAPING APPROACHES IN SCLC WITH THE LATEST ADVANCES IN LS- AND ES-DISEASE
34 min
LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND
32 min
THE ROLE OF IO ADDED TO CHEMORADIATION IN UNRESECTABLE STAGE III NSCLC
28 min
TAILORING IO IN RES. NSCLC: PERSONALIZED APPROACHES FOR IMPROVED OUTCOMES
36 min
UNLOCKING NEW POTENTIALS IN EGFR-MUTANT NSCLC
30 min
THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES
27 min
DEBATE: WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC?
31 min
ACTIONABLE GENOMIC ALTERATIONS – INCLUDING HER2 AND MET
26 min
TARGETING EGFR AND ALK IN NSCLC
26 min
CUTTING-EDGE DIAGNOSTIC TECHNIQUES AND EMERGING BIOMARKERS
24 min
Latest Advances in Frontline EGFR+ NSCLC
14 min
Open Discussion on Patient Cases
22 min
ILCS 2025
International Lung Cancer Summit 2025
Following the success of the previous International Lung Cancer Summits (ILCS), we warmly invite you to the 7th edition, expertly chaired by the distinguished duo Solange Peters and Alfredo Addeo. This premier hybrid conference continues its tradition of excellence by highlighting the latest breakthroughs in lung cancer treatment. With a global lineup of renowned speakers from the USA, France, UK, Spain, Ireland, Italy, Australia, Singapore, and Switzerland, the ILCS provides a unique platform for professionals from clinics, universities, and research institutes to engage, network, and collaborate. By leveraging digital platforms, the summit fosters a dynamic environment for sharing insights and advancing lung cancer care.
LED BY GLOBAL EXPERTS
Marius Ilié
France
Antonio Passaro
Italy
Antonio Calles
Spain
Xiuning Le
USA
Andrea Filippi
Italy
Noemi Reguart
Spain
Tom John
Australia
Alessandra Curioni
Switzerland
Patrick Forde
Ireland
Stephanie Saw
Singapore
Thomas Newsom-Davis
United Kingdom
Rami Manochakian
USA
CHECK OUT OUR PROGRAM
All Sessions Now Available on Demand
9.45
Welcome & Introduction by Chairs
Solange Peters & Alfredo Addeo
9.50
CUTTING-EDGE DIAGNOSTIC TECHNIQUES AND EMERGING BIOMARKERS
Marius Ilié (France)
10.10
TARGETING EGFR AND ALK IN NSCLC
Tom John (Australia)
10.35
OTHER ACTIONABLE GENOMIC ALTERATIONS – INCLUDING HER2 AND MET
Stephanie Saw (Singapore)
11.20
DEBATE: WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC?
-
ARGUING IN FAVOR OF AMIVANTAMAB + LAZERTINIB
Xiuning Le (USA)
-
ARGUING IN FAVOR OF OSIMERTINIB + CHEMO
Tom Newsom-Davis (UK)
11.50
THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES
Noemà Reguart (Spain)
14.15
TAILORING IO IN RESECTABLE NSCLC: PERSONALIZED APPROACHES FOR IMPROVED OUTCOMES
Patrick Forde (Ireland)
14.45
THE ROLE OF IO ADDED TO CHEMORADIATION IN UNRESECTABLE STAGE III NSCLC
ANDREA R. FILIPPI (Italy)
15.30
LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND
Alessandra Curioni (Switzerland)
15.50
RESHAPING OUR APPROACHES IN SCLC WITH THE LATEST ADVANCES IN LIMITED- AND EXTENSIVE-STAGE DISEASE
Rami Manochakian (USA)
16.20
Open Questions, Patient Cases & Guidelines
Panel Discussion With All
16.45
Closing Remarks by Chairs
Solange Peters & Alfredo Addeo
THE ILCS IS INTERNATIONALLY ACCREDITED WITH 5 CME CREDITS, EACH BY:
- EUROPEAN ACCREDITATION COUNCIL FOR CME (EACCME)
- SWISS SOCIETY OF MEDICAL ONCOLOGY
EACCME credits can be converted to AMA PRA Cat. 1 Credits.
INDUSTRY LED SYMPOSIA
12.30
Unlocking New Potentials in EGFR-mutant NSCLC
ANTONIO PASSARO (Italy)
Sponsors of ILCS 2025
